摘要
目的:分析普拉洛芬滴眼液在合并糖尿病的白内障手术治疗中的安全性和有效性。方法:选择2021年8月—2023年8月在本院治疗的92例合并糖尿病白内障患者作为研究对象,随机分为传统组和研究组,每组46例。传统组采用双氯芬酸钠治疗,研究组采用普拉洛芬滴眼液治疗,比较两组黄斑中心凹厚度、不良反应发生率、生活质量评分及痛感评分。结果:研究组治疗后3、7、9、14 d黄斑中心凹厚度高于传统组(P<0.05);研究组不良反应发生率低于传统组(P<0.05);研究组生理机能、生理职能、情感职能、精神健康评分高于传统组(P<0.05);研究组痛感评分低于传统组(P<0.05)。结论:普拉洛芬滴眼液能够改善合并糖尿病白内障患者术后黄斑中心凹厚度,降低并发症发生概率,减轻疼痛,提高生活质量。
Objective:To analyze the safety and efficacy of pranoprofen eye drops in cataract surgery with diabetes mellitus.Methods:A total of 92 patients with diabetic cataract treated in our hospital from August 2021 to August 2023 were selected as the research objects and randomly divided into the traditional group and the research group,with 46 patients in each group.The traditional group was treated with diclofenac sodium,and the study group was treated with pranoprofen eye drops.The macular foveal thickness,incidence of adverse reactions,quality of life score and pain score were compared between the two groups.Results:The thickness of macular fovea in the study group was higher than that in the traditional group at 3,7,9 and 14 days after treatment(P<0.05).The incidence of adverse reactions in the study group was lower than that in the traditional group(P<0.05).The scores of physiological function,physiological function,emotional function and mental health in the study group were higher than those in the traditional group(P<0.05).The pain score of the study group was lower than that of the traditional group(P<0.05).Conclusion:Pranoprofen eye drops can improve the thickness of macular fovea after cataract surgery in patients with diabetes,reduce the incidence of complications,reduce pain,and improve the quality of life.
作者
郑玉洁
王静
陈耀升
闫淑
ZHENG Yujie;WANG Jing;CHEN Yaosheng;YAN Shu(Pharmacy Department,Zhengzhou Second People's Hospital,Zhengzhou 450000,Henan,China;Ophthalmology Department,Zhengzhou Second People's Hospital,Zhengzhou 450000,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2024年第10期1855-1857,1869,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
基金
河南省医学科技攻关计划项目(编号:LHGJ20220819)。